CLINICAL TRIALS PROFILE FOR FIRMAGON
✉ Email this page to a colleague
All Clinical Trials for firmagon
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00451958 ↗ | A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy | Completed | Ferring Pharmaceuticals | Phase 3 | 2007-03-01 | Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years. |
| NCT00801242 ↗ | Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer | Completed | Ferring Pharmaceuticals | Phase 3 | 2008-12-01 | The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer. |
| NCT00833248 ↗ | Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer | Completed | Ferring Pharmaceuticals | Phase 3 | 2009-04-01 | The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months. |
| NCT00884273 ↗ | Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients | Completed | Ferring Pharmaceuticals | Phase 3 | 2009-08-01 | This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6 mg; plus anti-androgen flare protection, bicalutamide), to a novel GnRH antagonist, degarelix (240 mg starting dose/80 mg maintenance dose) with respect to mean percentage reduction in prostate volume. The hypothesis was that degarelix could decrease prostate size at least as effectively as the combination of a GnRH agonist with an anti-androgen for flare protection. |
| NCT00946920 ↗ | A Trial of Degarelix in Patients With Prostate Cancer | Completed | Ferring Pharmaceuticals | Phase 3 | 2009-06-01 | A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for firmagon
Condition Name
Clinical Trial Locations for firmagon
Trials by Country
Clinical Trial Progress for firmagon
Clinical Trial Phase
Clinical Trial Sponsors for firmagon
Sponsor Name
